Novartis Ag (NVS) Change in Taxes (2009 - 2026)
Novartis Ag (NVS) posted Change in Taxes of -$787.0 million for Q1 2026, up 19.78% sequentially from -$981.0 million in Q4 2025, and down 45.74% YoY from -$1.5 billion in Q1 2025.
Novartis Ag (NVS) Change in Taxes (2009 - 2026) Analysis & Trends
Novartis Ag has reported Change in Taxes for 18 years, with the latest figure at -$787.0 million in Q1 2026.
- Quarterly Change in Taxes fell 45.74% year-over-year to -$787.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 billion (down 19.68% YoY) and the FY2025 annual result came in at -$981.0 million, changed N/A from the prior year.
- Change in Taxes grew to -$787.0 million in Q1 2026 per NVS's latest filing, from -$981.0 million in the prior quarter.
- Over five years, Change in Taxes peaked at -$260.0 million in Q3 2022 and troughed at -$1.0 billion in Q4 2024.
- A 5-year average of -$578.7 million and a median of -$558.0 million in 2024 frame the typical range for Change in Taxes.
- The sharpest annual moves came in 2022 and 2024: Change in Taxes jumped 62.17% in 2022, then plunged 95.25% in 2024.
- Over 5 years, Change in Taxes stood at -$334.0 million in 2022, then decreased by 27.54% to -$426.0 million in 2023, then tumbled by 146.24% to -$1.0 billion in 2024, then advanced by 6.48% to -$981.0 million in 2025, then rose by 19.78% to -$787.0 million in 2026.
- According to Business Quant data, Change in Taxes over the past three periods registered -$787.0 million, -$981.0 million, and -$366.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.22 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -131.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 171.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -787.00 Mn |
| Mar 31, 2026 | -787.00 Mn |
| Dec 31, 2025 | -981.00 Mn |
| Dec 31, 2025 | -981.00 Mn |
| Sep 30, 2025 | -366.00 Mn |
| Sep 30, 2025 | -366.00 Mn |
| Jun 30, 2025 | -675.00 Mn |
| Jun 30, 2025 | -675.00 Mn |
| Mar 31, 2025 | -540.00 Mn |
| Mar 31, 2025 | -540.00 Mn |
| Dec 31, 2024 | -1.05 Bn |
| Dec 31, 2024 | -1.05 Bn |
| Sep 30, 2024 | -285.00 Mn |
| Sep 30, 2024 | -285.00 Mn |
| Jun 30, 2024 | -473.00 Mn |
| Jun 30, 2024 | -473.00 Mn |
| Mar 31, 2024 | -576.00 Mn |
| Mar 31, 2024 | -576.00 Mn |
| Sep 30, 2023 | -426.00 Mn |
| Sep 30, 2023 | -426.00 Mn |